首页 > 市场调查报告书 > 製药

甲状腺疾病治疗市场规模、份额和成长分析（按类型、药物、给药途径、分销管道和地区划分）－2026-2033年产业预测

市场调查报告书

商品编码

1897672

甲状腺疾病治疗市场规模、份额和成长分析（按类型、药物、给药途径、分销管道和地区划分）－2026-2033年产业预测

Thyroid Gland Disorders Treatment Market Size, Share, and Growth Analysis, By Type (Hypothyroidism, Hyperthyroidism), By Drug (Levothyroxine, Liothyronine), By Route of Administration, By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月26日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，甲状腺疾病治疗市场规模将达到 27 亿美元，到 2025 年将达到 28.1 亿美元，到 2033 年将达到 38.5 亿美元，在预测期（2026-2033 年）内，复合年增长率为 4%。

由于甲亢等疾病的盛行率不断上升、人口老化、医疗技术的进步以及人们对早期诊断和治疗意识提升，全球甲状腺疾病治疗市场正经历显着增长。个人化医疗和标靶治疗的引入进一步丰富了市场格局，其中北美和欧洲由于患病率高和医疗支出高，占据了相当大的市场份额。拉丁美洲和亚太地区的新兴经济体预计将因医疗基础设施的改善和宣传活动的开展而显着增长。远端医疗在内分泌咨询和日常护理中的应用提高了医疗服务的可近性，尤其是在专科服务匮乏的地区。儘管诊断资源短缺和治疗成本上升等挑战可能会阻碍市场发展，但该市场的成长潜力仍然强劲。

甲状腺疾病治疗市场驱动因素

全球甲状腺疾病盛行率的不断上升是推动治疗方法需求成长的主要因素。随着压力水平的升高和生活方式的改变，甲状腺功能亢进、甲状腺机能低下症和甲状腺癌等疾病的诊断率不断提高。此外，环境因素也加剧了这些健康问题的快速成长。甲状腺相关疾病的增加使得对有效治疗方法和干预措施的需求日益迫切，从而催生了一个不断扩大的甲状腺疾病治疗市场。医疗保健和製药公司正在积极响应这一领域日益增长的专业护理需求。

限制甲状腺疾病治疗市场的因素

甲状腺疾病治疗相关的经济负担是该市场面临的一大阻碍因素。接受长期治疗（例如放射性碘疗法或手术）的患者往往需要承担高昂的处方笺和手术费用。对于居住在医疗资源匮乏地区或缺乏足够医疗保险的患者而言，这种经济负担尤其突出。因此，许多患者难以获得所需的治疗，最终限制了他们的选择，并可能影响其整体治疗效果。解决这些治疗方法的可负担性和可近性问题对于改善甲状腺疾病患者的医疗服务至关重要。

甲状腺疾病治疗市场趋势

由于全球甲状腺疾病盛行率不断上升，甲状腺疾病治疗市场正经历显着的变革时期。需求的激增促使市场相关人员致力于开发创新治疗方法，以改善患者照护。製药公司正大力投资研发，旨在推出更有效、更经济且更符合个人需求的治疗方法。随着新疗法的出现，製造商优先考虑改善患者预后，力求在提高患者生活品质的同时，最大限度地减少副作用。这一趋势凸显了各方致力于解决甲状腺疾病复杂性的决心，并为持续的进步和治疗方案的发展奠定了坚实的基础。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

AbbVie Inc.（USA）
Amgen Inc.（USA）
GSK Plc（UK）
Merck KGaA（Germany）
Viatris Inc.（USA）
Novartis AG（Switzerland）
Pfizer Inc.（USA）
Takeda Pharmaceutical Company Limited（Japan）
Exelixis Inc.（USA）
Abbott Laboratories（USA）
Fresenius SE & Co. KGaA（Germany）
Jerome Stevens Pharmaceuticals Inc.（USA）
Lannett Co. Inc.（USA）

结论与建议

简介目录

Product Code: SQMIG35J2083

Thyroid Gland Disorders Treatment Market size was valued at USD 2.7 Billion in 2024 and is poised to grow from USD 2.81 Billion in 2025 to USD 3.85 Billion by 2033, growing at a CAGR of 4% during the forecast period (2026-2033).

The global thyroid gland disorders treatment market is experiencing significant growth, driven by an increase in prevalent conditions like hyperthyroidism, an aging population, advancements in medical technology, and heightened awareness regarding early diagnosis and treatment. The introduction of personalized medicine and targeted therapies further enriches the market landscape, with North America and Europe holding substantial share due to higher incidence rates and healthcare expenditure. Emerging economies in Latin America and Asia-Pacific are poised for notable growth, supported by improved healthcare infrastructures and awareness initiatives. The adoption of telemedicine for endocrinology consultations and routine care enhances accessibility, especially where specialist services are scarce. Challenges, such as limited diagnostic resources and high treatment costs, may hinder progress, yet the market's potential growth remains robust.

Top-down and bottom-up approaches were used to estimate and validate the size of the Thyroid Gland Disorders Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Thyroid Gland Disorders Treatment Market Segments Analysis

Global Thyroid Gland Disorders Treatment Market is segmented by Type, Drug, Route of Administration, Distribution Channel and region. Based on Type, the market is segmented into Hypothyroidism and Hyperthyroidism. Based on Drug, the market is segmented into Levothyroxine, Liothyronine, Propylthiouracil, Imidazole-based compounds and Others. Based on Route of Administration, the market is segmented into Oral, Intravenous and Others. Based on Distribution Channel, the market is segmented into Wholesale Distribution, Retail Stores, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Thyroid Gland Disorders Treatment Market

The rising prevalence of thyroid disorders globally is significantly driving the demand for treatment options. Conditions such as hyperthyroidism, hypothyroidism, and thyroid cancer are increasingly being diagnosed, largely due to heightened stress levels and lifestyle changes affecting individuals. Furthermore, environmental factors have contributed to the surge in these health issues. This growing incidence of thyroid-related ailments has created an urgent need for effective therapies and interventions, leading to an expansion in the market dedicated to treating thyroid gland disorders. Healthcare providers and pharmaceutical companies are responding to the escalating requirement for specialized medical care in this area.

Restraints in the Thyroid Gland Disorders Treatment Market

The financial burden associated with thyroid gland disorder treatments poses a significant restraint in this market. Patients undergoing long-term therapies, such as radioactive iodine treatments or surgical interventions, often face substantial costs for their prescriptions and procedures. This financial strain can be particularly pronounced for individuals in underserved regions or those without adequate health insurance coverage. Consequently, many patients may experience challenges in accessing necessary treatments, ultimately limiting their options and impacting overall patient outcomes. Addressing the affordability and accessibility of these treatment modalities is crucial for improving care for those affected by thyroid disorders.

Market Trends of the Thyroid Gland Disorders Treatment Market

The thyroid gland disorders treatment market is experiencing a significant transformation driven by increasing incidence rates worldwide. This surge in demand has prompted market players to focus on developing innovative treatment options that enhance patient care. Pharmaceutical companies are investing heavily in research and development, aiming to introduce more effective and affordable therapies tailored to individual needs. As new treatment modalities emerge, manufacturers are prioritizing improved patient outcomes, seeking to enhance quality of life while minimizing adverse effects. This trend underscores a commitment to addressing the complexities of thyroid disorders, fostering a robust landscape for ongoing advancements and therapeutic solutions.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies

Global Thyroid Gland Disorders Treatment Market Size by Type & CAGR (2026-2033)

Market Overview
Hypothyroidism
Hyperthyroidism

Global Thyroid Gland Disorders Treatment Market Size by Drug & CAGR (2026-2033)

Market Overview
Levothyroxine
Liothyronine
Propylthiouracil
Imidazole-based compounds
Others

Global Thyroid Gland Disorders Treatment Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Oral
Intravenous
Others

Global Thyroid Gland Disorders Treatment Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Wholesale Distribution
Retail Stores
Online Pharmacy
Others

Global Thyroid Gland Disorders Treatment Market Size & CAGR (2026-2033)

North America (Type, Drug, Route of Administration, Distribution Channel)
- US
- Canada
Europe (Type, Drug, Route of Administration, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Drug, Route of Administration, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Drug, Route of Administration, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Drug, Route of Administration, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GSK Plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exelixis Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius SE & Co. KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jerome Stevens Pharmaceuticals Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lannett Co. Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments